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Background:  Late  gadolinium  enhancement  (LGE)  of  cardiac  magnetic  resonance  imaging  (MRI)
represents  myocardial  ﬁbrosis  and  may  be  related  to  the  clinical  outcome  of  various  heart
diseases.  This  study  evaluated  the  relationship  between  LGE  and  cardiac  events  in  hypertrophic
cardiomyopathy  (HCM)  using  a  new  scoring  method.
Methods  and  results:  This  study  retrospectively  followed  46  HCM  patients  without  heart  failure
symptoms  for  3.8  ±  1.8  years.  Gadolinium-enhanced  cardiac  MRI  was  performed  in  all  patients.
Cardiac events  including  newly  developed  heart  failure  or  ventricular  tachyarrhythmia  were
evaluated  during  the  follow-up  period.  We  evaluated  the  predictive  factors  to  identify  the
patients with  cardiac  events.  None  of  the  risk  factors  reported  to  be  related  to  poor  outcome
or the  existence  of  LGE  alone  could  predict  cardiac  events,  which  might  be  due  to  the  small
number  of  subjects  investigated  in  this  study.  A  new  scoring  method  for  LGE-positive  areas  (LGE
score) was  applied  and  higher  LGE  score  can  predict  cardiac  events  in  this  study  population.
Conclusions:  The  proposed  LGE  score  for  cardiac  MRI  is  considered  to  be  a  potentially  valid
method for  assessing  cardiac  events  in  HCM  patients.
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ntroductioneft  ventricular  hypertrophy  is  thought  to  be  a  risk  factor
or  future  cardiovascular  events  such  as  ischemic  heart  dis-
ase,  heart  failure,  and  ventricular  tachyarrhythmia  [1].











































































































yocardial  ﬁbrosis  and  scar  formation  are  frequently
bserved  in  a  hypertrophied  myocardium,  and  these  abnor-
alities  can  cause  contractile  dysfunction  and  arrhythmo-
enesis  [2].  Recent  advances  in  cardiac  magnetic  resonance
maging  (MRI)  have  enabled  the  detection  of  myocardial
brosis  or  scar  formation  using  late  gadolinium  enhance-
ent  (LGE)  in  vivo  [3—7]. Hypertrophic  cardiomyopathy
HCM)  is  one  of  the  important  causes  of  left  ventricular
ypertrophy  and  sudden  cardiac  death,  possibly  due  to  ven-
ricular  arrhythmia  [8—11]. HCM  patients  who  die  suddenly
requently  have  myocardial  scarring  found  upon  autopsy  [5].
he  presence  of  LGE  in  cardiac  MRI  has  been  correlated  with
all  thickness,  cardiac  function,  and  ventricular  arrhyth-
ia  in  HCM  patients  [6,7,12].  Therefore,  the  estimation  of
GE  obtained  from  cardiac  MRI  is  an  important  factor  that
an  be  optimized  to  predict  future  risk  or  to  select  treat-
ent  strategies  for  HCM  patients  [8].  Recently,  two  papers
nvestigated  the  relationship  between  LGE  and  cardiovascu-
ar  events  and  mortality  in  HCM  patients  [13,14].  One  study
emonstrated  a  relationship  between  the  presence  of  LGE
nd  the  composite  endpoint  including  cardiovascular  death
13].  Another  study  noted  that  the  presence  of  LGE  yielded
n  odds  ratio  of  5.47  for  all-cause  mortality  and  of  8.01  for
ardiac  mortality  [14]. However,  both  studies  included  a  sig-
iﬁcant  number  of  heart  failure  patients  [New  York  Heart
ssociation  (NYHA)  functional  class  II—III/IV]  in  their  study
opulation  and  there  was  no  information  regarding  the  rela-
ionship  between  LGE  and  cardiovascular  events  in  patients
ithout  heart  failure  symptoms.
The  present  study  investigated  the  role  of  LGE  on  cardiac
vents  in  HCM  patients  without  heart  failure  symptoms.  This
tudy  hypothesized  that  larger  involvement  of  LGE  can  be
elated  to  cardiac  events.  Therefore  a  new  scoring  method
as  developed  for  the  estimation  of  LGE  areas  (LGE  score)
ecause  there  is  no  consensus  regarding  the  quantitative
stimation  of  LGE  in  HCM  [15,16].  The  predictive  value  of
arious  factors  was  estimated  to  identify  cardiac  events.
ethods
opulation
his  study  retrospectively  studied  46  consecutive  HCM
atients  without  heart  failure  symptoms  who  met  the  cri-
eria  described  below  and  underwent  cardiac  MRI  at  The
ikei  University  Hospital  between  2003  and  2006.  The  study
ncluded  only  the  HCM  patients  who  were  diagnosed  accord-
ng  to  the  World  Health  Organization/International  Society
nd  Federation  of  Cardiology  deﬁnition  of  cardiomyopathies
17].  The  diagnosis  was  based  on  echocardiographic  ﬁndings
f  asymmetrical  left  ventricular  hypertrophy  in  the  areas
f  both  the  ventricular  septum  and  the  anterolateral  free
all  (Maron  type  III)  without  any  other  cardiac  or  systemic
iseases  that  produce  left  ventricular  hypertrophy  [18]. The
eft  ventricular  ejection  fraction  and  maximal  wall  thickness
ere  observed  by  routine  echocardiography.  These  patients
ere  not  found  to  have  ischemic  heart  disease  by  either
oronary  angiography  or  myocardial  stress  scintigraphy  or
readmill  exercise  testing.
This  study  protocol  complies  with  the  ethical  guide-
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riori  approval  by  the  institution’s  human  research  com-
ittee  (Approval  number  17-0764497).  Written  informed
onsent  was  provided  by  all  patients.
ardiac  MRI
he  cardiac  MR  examinations  were  performed  on  a  1.5  T
linical  MR  system  (MAGNETOM  Avanto,  Siemens  Medical
olutions,  Erlangen,  Germany).  Scout  images  were  acquired
nitially  to  identify  the  cardiac  axes.  Breath-hold  steady-
tate  free  precession  (SSFP)  images  were  acquired  in  6-mm
ong-axis  slices  and  sequential  7-mm  short-axis  slices  (no
ap)  from  the  atrioventricular  ring  to  the  apex  for  assess-
ent  of  left  ventricular  mass  index:  FOV  400  mm  ×  325  mm,
ixel  size  2.7  mm  × 1.6  mm,  TE  (echo  time)/TR  (repetition
ime)  1.2/73.8  ms,  ﬂip  angle  65◦,  because  calculation  of  the
entricular  mass  using  echocardiography  could  be  incorrect
f  there  is  asymmetrical  hypertrophy.  Subsequently,  LGE  MR
mages  were  acquired  in  the  same  short-axis  orientations
s  above  described  SSFP  images,  15  min  after  injection  of
.2  mmol/kg  of  gadolinium-DTPA  (Magnevist,  Bayer  Schering
harma  AG,  Berlin,  Germany),  using  an  inversion-recovery
radient  echo  sequence:  FOV  340  mm  ×  276  mm,  pixel  size
.4  mm  × 1.3  mm,  slice  thickness  8  mm,  TE/TR  4.2/700  ms,
ip  angle  25◦. The  inversion  time  ranged  typically  from  300
o  450  ms  which  was  chosen  to  correspond  to  the  null  normal
yocardial  signal  of  LGE  images  [19]. Cardiac  MR  scans  were
valuated  on  a  commercially  available  workstation  (Multi
odality  Working  Place,  Siemens  Medical  Solutions,  Erlan-
en,  Germany),  and  the  areas  with  signal  intensity  above
he  average  of  the  normal  myocardium  plus  2  standard  devi-
tions  were  deﬁned  as  LGE-positive.  The  LGE-positive  areas
hat  were  identiﬁed  by  the  software  program,  but  did  not
ppear  to  be  LGE-positive  by  the  investigator  were  excluded
anually.
coring  of  LGE  images
hree  short-axis  slices  (basal,  mid,  and  apical  portions)  were
elected  to  detect  16  areas  of  the  left  ventricle  recom-
ended  for  the  tomographic  imaging  of  the  heart  without
n  apical  portion  (see  the  study  limitations)  [20]. Each  of
he  deﬁned  16  areas  was  subdivided  into  3  segments  as
ub-epicardial,  mid-wall,  and  sub-endocardial  areas.  All  of
he  total  48  segments  in  3  horizontal  portions  of  MRI  slices
18  in  the  basal,  18  in  the  mid,  and  12  in  the  apical  por-
ions)  were  inspected,  and  the  number  of  segments  with
GE  was  counted  and  scored  relative  to  the  total  48  points
LGE  score)  (Fig.  1).
isk  stratiﬁcation
he  existence  of  syncope  and  a  family  history  of  HCM  or  sud-
en  death  are  thought  to  be  important  determinants  of  the
rognosis  of  HCM  patients  [6];  therefore  these  clinical  fea-
ures  were  surveyed  in  the  current  population  using  medical
ecords.  A  patient  was  recognized  to  be  ‘‘family  history  pos-
tive’’  if  the  patient  had  a  family  history  of  HCM  or  sudden
eath  within  the  ﬁrst  degree  of  kinship.  The  presence  of  5
r  more  runs  of  ventricular  premature  beats  on  ambulatory










tFigure  1  (A)  The  left  ventricular  wall  is  divided  into  48  segm
(B) Detection  of  the  LGE-positive  area  and  calculation  of  the  LG
electrocardiogram  (ECG)  was  counted  as  positive  for  ventric-
ular  tachyarrhythmia.  Severe  left  ventricular  hypertrophy
(wall  thickness  of  more  than  30  mm)  was  also  identiﬁed  using
echocardiography.  Overall,  4  out  of  5  previously  reported
clinical  risk  factors  for  sudden  death  were  identiﬁed  [6].
Patients  who  had  at  least  one  of  the  risk  factors  were  deﬁned
as  the  risk  group.Cardiac  events
The  patients’  outcome  was  observed  using  medical  records




t according  to  the  procedure  described  in  the  Methods  section.
ore.  LGE,  late  gadolinium  enhancement.
nitial  cardiac  MRI  study.  There  was  no  incidence  of  death,
ardiac  arrest,  or  implantable  cardioverter  deﬁbrillator
mplantation  in  the  study  population.  Cardiac  events  were
eﬁned  as  newly  developed  heart  failure  (more  than  NYHA
unctional  class  II)  or  newly  identiﬁed  ventricular  tach-
arrhythmia  (more  than  5  runs  of  ventricular  premature
eats).  Heart  failure  was  diagnosed  to  require  either  hospi-
alization  or  intensive  medical  treatment  due  to  a  worsening
f  heart  failure  symptoms.  Ventricular  tachyarrhythmia  was
eﬁned  by  Holter  ECG  which  was  performed  either  during






























































ontinuous  variables  are  expressed  as  the  mean  ±  standard
eviation  (SD).  Categorical  data  are  presented  as  the  per-
entage  frequency.  Student’s  t  test  was  used  to  compare
ontinuous  variables,  and  the  chi-square  test  was  used  for
ategorical  variables.  A  Kaplan—Meier  analysis  was  per-
ormed  to  compare  the  cardiac  event  rate  among  various
ata  sets  and  log-rank  test  was  used  to  verify  signiﬁcant
ifferences.  Receiver-operator  characteristic  (ROC)  curve
nalysis  was  performed  to  identify  the  cut-off  value  of  the
GE  score.  All  tests  of  signiﬁcance  were  two-sided,  and  a  p-
alue  of  less  than  0.05  was  considered  to  be  signiﬁcant.  All
nalyses  were  performed  using  the  SPSS  software  package,
ersion  11.5  (SPSS  Inc.,  Chicago,  IL,  USA).
esults
atient  characteristics
he  baseline  characteristics  of  the  46  patients  are  summa-
ized  in  Table  1.  Their  mean  age  was  60  ±  10  years  (range
rom  32  to  78  years),  and  87%  were  male.  All  patients  were
lassiﬁed  as  being  NYHA  functional  class  I  at  the  time  of
ardiac  MRI  examination.  The  mean  left  ventricular  ejec-
ion  fraction  was  71.5  ±  5.5%.  Patients  with  at  least  one  of
he  risk  factors  (risk  group)  accounted  for  26%  of  all  patients,
nd  all  of  these  patients  were  found  to  be  in  the  LGE-positive
roup.  There  were  no  statistically  signiﬁcant  differences  in
atient  characteristics  between  the  LGE-negative  group  and
he  LGE-positive  group  except  for  risk  stratiﬁcation.istribution  of  the  LGE-positive  area  and  LGE  score
n  total,  34  patients  were  identiﬁed  as  having  LGE-





Table  1  Characteristics  of  the  study  population  before  the  study
LGE-negative  (n  =  12)  
Age  (years)  59  ±  13  
Male, n  (%)  10  (83)  
Body mass  index  (g/m2)  23.9  ±  4.4  
LVMI (g/m2)  119.5  ±  43.5  
EF (%)  71.6  ±  5.5  
Risk factors
Syncope,  n  (%)  0  
Family history,  n  (%) 0  
Ventricular  tachyarrhythmia,  n  (%) 0
Maximal wall  thickness  (mm) 18.2  ±  4.7  
Severe hypertrophy,  n  (%) 0
Risk group,  n  (%)  0  
Medication
Beta-blocker  use,  n  (%)  5  (42)  
ACEI/ARB use,  n  (%)  6  (50)  
Calcium blocker  use,  n  (%)  3  (25)  
The risk group was deﬁned as patients who had at least one of the ri
or severe hypertrophy); LGE, late gadolinium enhancement; ACEI, ang
blocker; LVMI, left ventricular mass index; EF, ejection fraction.A.  Nojiri  et  al.
omenclature  for  tomographic  imaging  of  the  heart  was
sed  to  plot  the  number  of  segments  with  LGE-positive
reas  in  all  of  the  LGE-positive  patients  using  a  bull’s-eye
epresentation  (Fig.  2A).  Each  number  depends  on  the  num-
er  of  subjects  and  is  only  used  for  qualitative  comparison
urposes.  The  LGE-positive  areas  were  mainly  distributed
mong  septal  areas,  particularly  in  the  junction  between
he  interventricular  septum  and  the  right  ventricular  free
all,  where  hypertrophied  myocardium  was  detected  in  this
tudy  population.  This  ﬁnding  is  consistent  with  previous
tudies  [21,22].  In  addition,  the  distribution  of  the  LGE-
ositive  area  was  analyzed  in  3  layers  of  the  myocardial  wall
i.e.  sub-epicardial,  mid-wall,  and  sub-endocardial  areas).
GE-positive  areas  were  frequently  observed  at  the  mid-wall
nd  sub-epicardial  areas,  and  they  were  rarely  seen  in  the
ub-endocardial  area  (Fig.  2B).
The  number  of  LGE-positive  segments  in  the  48  segments
f  the  left  ventricle  deﬁned  in  the  Methods  was  counted  in
ach  patient,  and  the  LGE  score  was  calculated.  The  highest
core  of  the  34  patients  in  the  LGE-positive  group  was  21,
nd  the  lowest  score  was  1  (7.56  ±  5.78,  n  =  34).  The  dis-
ribution  of  the  LGE  score  among  all  patients  is  shown  in
ig.  2C.
rediction  of  cardiac  events
here  were  5  cases  of  cardiac  events  in  the  study  popu-
ation  during  the  follow-up  period  (Table  2).  All  patients
ere  divided  into  2  groups  with  or  without  risk  factors,  and
aplan—Meier  curves  were  made  in  terms  of  the  existence  of
ardiac  events.  A  log-rank  test  revealed  that  none  of  the  risk
actors  (syncope,  family  history,  ventricular  tachyarrhyth-
ia,  and  severe  hypertrophy)  could  predict  cardiac  events
tatistically  (Fig.  3A—D).  The  risk  group  (at  least  one  of  the
isk  factors)  also  did  not  predict  cardiac  events  (Fig.  3E).
ll  cardiac  events  were  observed  in  the  LGE-positive  group;
.
LGE-positive  (n  =  34)  Total  (n  =  46)  p-value
61  ±  9  60  ±  10  0.58
30  (88)  40  (87)  0.67
24.5  ±  3.1  24.3  ±  3.4  0.64
116.4  ±  37.8  117.2  ±  38.8  0.83
71.5  ±  5.6  71.5  ±  5.5  0.98
3  (9)  3  (7)  0.29
5  (14)  5  (11)  0.16
5  (14)  5  (11)  0.16
19.9  ±  3.6  19.5  ±  3.9  0.24
1  (3)  1  (2)  0.55
12  (35)  12  (26)  0.017
19  (56)  24  (52)  0.4
21  (62)  27  (59)  0.48
10  (29)  13  (28)  0.77
sk factors (syncope, family history, ventricular tachyarrhythmia,
iotensin-converting enzyme inhibitor; ARB, angiotensin receptor
Late  gadolinium  enhancement  and  cardiac  events  in  HCM  
Figure  2  (A)  Distribution  of  the  LGE-positive  area  in  a  bull’s-
eye representation.  A  16  segment  division  was  performed
according  to  Fig.  1A.  Each  number  represents  the  sum  of  the
LGE-positive  areas  of  3  layers  in  each  segment  from  all  study
patients.  (B)  The  distribution  of  the  LGE-positive  areas  in  three
wall subdivisions  in  each  of  the  16  segments  (see  the  details  in
the Methods  section).  (C)  The  distribution  of  the  LGE  score  in







































Table  2  Characteristics  of  the  patients  with  cardiac  events.
Case  #  Age  Pre-study  characteristics  E
Severe  LVH  Pre-VT  Family  history  Pre-syncope
4  73  −  +  −  −  7
7 51  −  −  +  −  7
23 63  −  −  −  −  5
30 57  −  −  −  −  7
39 60  −  −  −  −  8
CHF, congestive heart failure; VT, ventricular tachyarrhythmia; LVH, lef
wall thickness; LVMI, left ventricular mass index; LGE, late gadolinium257
owever,  the  difference  did  not  reach  statistical  signiﬁcance
Fig.  3F).  The  absence  of  any  statistical  signiﬁcance  might
e  due  to  the  small  number  of  subjects  investigated  in  this
tudy.  The  LGE  score  was  then  used  to  identify  cardiac
vents  in  the  study  population.  A  receiver-operator  char-
cteristic  (ROC)  curve  analysis  revealed  the  area  under  the
urve  was  0.754  (95%  CI,  0.565—0.942,  p  =  0.066).  A  cut-off
alue  of  8  for  the  LGE  score  was  determined  to  have  80%
ensitivity  and  78%  speciﬁcity  for  identifying  cardiac  events
Table  3).  This  cut-off  value  was  used  to  divide  the  patients
nto  a  higher  LGE  score  group  (LGE  score  ≥  8)  and  a  lower
GE  score  group  (LGE  score  ≤  7).  A  Kaplan—Meier  analysis
evealed  that  the  rate  of  cardiac  events  was  signiﬁcantly
ncreased  in  the  higher  LGE  score  group  (p  =  0.0035,  log-rank
est;  Fig.  4).
iscussion
he  present  study  proposed  a  new  method  for  the  analysis  of
GE-positive  areas  using  the  LGE  score.  The  major  ﬁnding  of
his  study  was  that  the  LGE  score  can  predict  cardiac  events
n  patients  without  heart  failure  symptoms.
istribution  of  LGE-positive  areas  using  the  LGE
core
he  current  method  using  the  analysis  of  48  segments
f  LGE-positive  areas  identiﬁed  that  mid-wall  and  sub-
picardial  areas  were  more  frequently  positive  than  the
ub-endocardial  area.  This  is  in  contrast  to  patterns  found
n  patients  with  myocardial  infarction,  because  the  sub-
ndocardial  area  is  the  most  frequently  affected  in  these
atients  [23]. A  recently  proposed  ‘‘ischemic  pattern’’
f  LGE  areas  also  includes  subendocardial  or  transmural
nvolvement  [3].  Studies  including  post-mortem  histology
r  surgically  available  tissue  analysis  have  clearly  indicated
hat  LGE-positive  areas  in  HCM  can  reﬂect  myocardial  scar-
ing  or  interstitial  ﬁbrosis  [24,25].  These  abnormalities  may
e  due  to  micro-vascular  ischemia,  which  is  also  deﬁned  as
mall  coronary  arteriole  dysplasia  [25], the  distribution  of
hich  is  not  correlated  with  the  perfusion  of  the  epicardial
oronary  artery.
F  (%)  Max  WT  (mm)  LVMI  (g/mm2)  LGE  score  Event  type
1  19.8  71.7  11  CHF
6  22  148.8  8  VT
8  15.4  134.8  11  CHF
3  20.7  111.3  2  VT
0  24.7  148.8  19  VT
t ventricular hypertrophy; EF, ejection fraction; Max WT, maximal
 enhancement.
258  A.  Nojiri  et  al.
Figure  3  Kaplan—Meier  analysis  of  the  cardiac  event-free  rate  among  various  data  sets.  (A)  With  or  without  syncope  (pre-syncope).
( icula






















SB) With  or  without  family  history.  (C)  With  or  without  ventr
entricular hypertrophy  (LVH).  (E)  With  or  without  any  risk  fact
GE  score  and  cardiac  events
he  current  study  found  that  the  cardiac  events  (including
ewly  developed  heart  failure  or  newly  identiﬁed  ventricu-
ar  tachycardia)  occurred  more  often  in  the  higher  LGE  score
roup.  Heart  failure  is  an  important  complication  of  HCM  and
an  be  related  to  the  extent  of  ﬁbrosis  [6,13,26,27]. Ven-
ricular  tachyarrhythmia  can  also  produce  poor  outcome  in
CM  patients  and  ﬁbrous  tissue  can  promote  re-entrant  cir-
uit  to  provoke  ventricular  arrhythmia  [28]. Cardiac  events
ould  not  be  predicted  using  previously  reported  risk  fac-
ors  [6].  Moreover,  the  cardiac  risk  group  in  which  patients
ho  had  at  least  one  of  the  risk  factors  also  did  not  predict
ardiac  events.  There  was  no  deterioration  of  cardiac  sys-




Ir  tachyarrhythmia  (pre-VT).  (D)  With  or  without  severe  left
(F)  With  or  without  late  gadolinium  enhancement  (LGE).
evealed  that  the  extent  of  LGE  was  related  to  the  left  ven-
ricular  diastolic  function  in  HCM  [29,30].  Therefore,  cardiac
vents  in  the  present  population  could  be  related  to  dias-
olic  dysfunction.  However,  whether  the  extent  of  LGE  is  an
ndependent  predictor  of  diastolic  function  will  need  to  be
valuated  in  further  studies  because  the  current  study  did
ot  evaluate  the  diastolic  function  of  the  patients.
tudy  limitationshis  study  selected  patients  without  heart  failure  symp-
oms  that  had  left  ventricular  hypertrophy  within  both  the
entricular  septum  and  anterolateral  free  wall  (Maron  type
II).  Furthermore,  only  HCM  patients  who  had  preserved
Late  gadolinium  enhancement  and  cardiac  events  in  HCM  259
Table  3  Evaluation  of  the  cut-off  value  of  LGE  score  to  identify  cardiac  events.
LGE  score  Odds  ratio  (95%  CI)  Sensitivity  (95%  CI)  Speciﬁcity  (95%  CI)
7  10.909  (1.418—79.160)  0.800  (0.397—0.963)  0.732  (0.683—0.752)
8 14.222  (1.814—104.591)  0.800  (0.399—0.963)  0.780  (0.732—0.800)
9 5.333  (0.903—31.114)  0.600  (0.244—0.877)  0.780  (0.737—0.814)
LGE, late gadolinium enhancement; CI, conﬁdence interval.









motion score. J Cardiol 2008;51:95—105.rate  in  the  different  late  gadolinium  enhancement  (LGE)  score
groups  (LGE  score  ≤  7  and  LGE  score  ≥  8).
systolic  function  were  included  (ejection  fraction  >  55%).
These  selection/exclusion  criteria  might  have  biased  the
present  study.  The  number  of  patients  was  also  relatively
small  because  of  the  patient  selection.  The  absence  of  sta-
tistical  signiﬁcance  between  the  cardiac  events  and  the  risk
factors  or  the  existence  of  LGE  might  be  due  to  the  small
number  of  subjects  investigated  in  this  study.  In  addition,
no  multivariate  analysis  could  be  applied  due  to  the  small
number  of  events.  Therefore,  it  will  be  necessary  to  inves-
tigate  the  validity  of  the  use  of  the  LGE  score  method  in
a  wider  population  of  HCM  patients,  including  those  with
heart  failure  symptoms,  poor  ventricular  function  or  with
an  extent  of  hypertrophy  other  than  Maron  type  III.  Recent
studies  have  used  workstations  to  automatically  evaluate
the  LGE-positive  areas  in  cardiac  MRI  [16,31].  It  might  there-
fore  be  easier  and  more  reliable  to  use  such  workstations,
but  the  LGE  score  method  can  also  be  used  to  estimate  the
distribution  of  LGE-positive  areas.
The  current  study  population  consisted  of  relatively
benign  patients  with  no  death  during  the  follow-up,
thus,  only  soft  end-points  were  evaluated  (namely,  newly
developed  heart  failure  or  newly  identiﬁed  ventricular
tachycardia).  However,  the  observed  association  of  a  poor
outcome  with  a  higher  LGE  score  in  HCM  patients  without
heart  failure  symptoms  is  nevertheless  an  important  ﬁnding.
Conclusion
The  present  study  proposed  a  new  scoring  method  for  the
analysis  of  LGE-positive  areas  found  on  cardiac  MRI.  The  LGE
score  method  would  be  useful  for  predicting  cardiac  events
in  HCM  patients.
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